New Indications For ENPP1 Inhibitors, Part Two

Researchers at UCLA have observed that ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1)is highly expressed by cardiac fibroblasts in the myocardial injury site. During injury, ENPP1 is upregulated in these cardiac fibroblasts and leads to disrupted wound healing. The developed small molecule inhibitors and monoclonal antibodies antibody targeting the catalytic domain of ENPP1 prevent this disruption and present new therapeutic strategies for the preservation of cardiac function after MI.

In addition, the monoclonal antibodies can be used to screen for PXE. UCLA researchers have identified drugs in clinical use that are not known to inhibit ENPP1 or prevent ectopic calcification. These commercially used FDA approved prescription drugs and the can decrease ectopic calcification, coupled with the use of ENPP1 inhibitors, can prevent calcification and blindness.

Abstract

UCLA researchers in the Department of Medicine have developed small molecule ENPP1 inhibitors and monoclonal antibodies for treating myocardial infarction and ocular calcification.

Website

https://techtransfer.universityofcalifornia.edu/NCD/30530.html?utm_source=AUTMGTP&utm_medium=webpage&utm_term=ncdid_30530&utm_campaign=TechWebsites

Advantages

  • Preservation of cardiac function
  • Prevention of mineralization and calcification in eyes due to PXE

Potential Applications

  • Treatment for myocardial infarction
  • Treatment for Pseudoxanthoma elasticum (Groenblad syndrome) (PXE) associated retinal damage and blindness

Contact Information

Name: UCLA Technology Development Group

Email: ncd@tdg.ucla.edu

Phone: 310.794.0558